1. Home
  2. Weight Management & Metabolism
  3. Orforglipron
Orforglipron
Weight Management

Orforglipron

Orforglipron · Oral small-molecule GLP‑1 receptor agonist

An oral, non-peptide GLP‑1 receptor agonist. Not a peptide.

Price confirmed by your advisor.

Available on request in Canada

Ask an advisor
Non-binding request. An advisor contacts you and the partner pharmacy checks whether and how it can proceed. A valid prescription, or an assessment through an authorized telemedicine service, may be required.
  • Partner pharmacy
  • Personal assistance
  • Discreet delivery

Shipping & Delivery

  • Normally dispatched within 24 hours of payment confirmation.
  • UPS Express · C$25 · Approx. 7–9 business days
  • Registered Mail · C$15 · Approx. 14–20 business days
Research status

What is known so far

Orforglipron is an oral small-molecule (non-peptide) GLP‑1 receptor agonist developed for obesity and type 2 diabetes.

Its authorization status in Canada is under review. This page is informational only and does not describe proven clinical benefits.

Documents

Product information

Patient information leafletNot available: authorization status under review
Summary of Product CharacteristicsNot available: authorization status under review
References

Sources

  1. US Food and Drug Administration. Novel Drug Approvals for 2026: Foundayo (orforglipron), 1 April 2026.
Related
Weight Management
  • CagriSema
    Cagrilintide + semaglutide

    CagriSema

    Research compound · information only

    On request

  • Cagrilintide
    Cagrilintide

    Cagrilintide

    Research compound · information only

    On request

  • Victoza
    Liraglutide

    Victoza

    Pen · 1, 2 or 3 pens

    On request

    fromC$170